Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma

Journal of Immunotherapy

Volumn 24, Issue 2, 2001, Pages 114-121

  Morecki, S ^a   Yacovlev, E ^a   Gelfand, Y ^a   Uzi, I ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cell therapy; Mammary carcinoma; Tumor immune cells

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; LUNG ALVEOLUS CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY TESTING; IMMUNIZATION; IMMUNOTHERAPY, ADOPTIVE; LUNG; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM METASTASIS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035123679     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200103000-00005     Document Type: Article

References (42)

1. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
2. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
3. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
4. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
5. Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation
6. Role of natural killer cells in cancer
7. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
8. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene
9. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia
10. T-cell recognition of self peptides as tumor rejection antigens
11. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy
12. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells
13. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma
14. Adoptive immunotherapy mediated by anti-TCR/IL-2 activated tumor-draining lymph node cells
15. Spontaneous and IL-2 induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens
16. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantion
17. Graft-vs-tumor and graft-vs-leukemia in patient with concurrent breast cancer and acute myelocytic leukemia
18. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
19. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation
20. Lymphocyte transfusion therapy for cancer patients
21. Allogeneic cell therapy for a murine mammary carcinoma
22. Heterogeneity of tumor cells from a single mouse mammary tumor
23. Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation
24. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2
25. Induction of graft-vs-tumor effect in a murine model of mammary adenocarcinoma
26. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation
27. Adoptive immunotherapy of murine lymphosarcoma: Comparative study using allo-immune or tumor-immune T cells
28. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation
29. Role of cytokines in GVL (Esb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice
30. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine
31. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma
32. Use of recombinant interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. 1. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2 activated cell-mediated immunotherapy
33. Transplantation of allogeneic bone marrow without graft-vs-host disease using total lymphoid irradiation
34. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
35. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells
36. Allospecific CDS+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease
37. Graft-vs-host and graft-vs-leukemia reactions after delayed infusions of donor T-subsets
38. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity
39. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice
40. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
41. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-vs-leukemia
42. Adoptive cellular immunotherapy for EBV lymphoproliferative disease